Editas Medicine Inc (EDIT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.76 (+1.47%), Market cap $0.26B, 52-week low–high $1.49 ~ $4.15.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the
Financial statements, price targets, institutional (13F) holdings and related news for Editas Medicine Inc are updated in real time on BlackAll Trade.
Editas Medicine Inc trades at $2.76 (+1.47%). Real-time quotes and charts are available on BlackAll Trade.
Editas Medicine Inc has a market cap of about $0.26B.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene edi